Markers of acute kidney injury: applying theory to practice by Soto, K et al.
MARKERS	  OF	  ACUTE	  KIDNEY	  INJURY	  
Applying	  theory	  to	  prac?ce	  
Soto K, Frade F, Papoila AL, Tiago Ribeiro et al.!
!
Servico de Nefrologia e de Urgencias!
 HOSPITAL FERNANDO FONSECA !
DEPARTMENTO DE BIOESTATISTICA DA UNIVERSIDADE NOVA, DE LISBOA!
INSTITUTO SUPERIOR DE ENGENHARIA DE LISBOA !
FROM BEDSIDE TO BENCH...!
!   CASES!
!   REVIEWING OUR KNOWLEDGE !
!  CHANGING CONCEPTS!
!   UNDERSTANDING ABOUT BIOMARKERS!
!   MOVING FORWARD!
	  	   AGE! COMORB!CKD!CVD !DM!CAUSE of ADM!no-RENAL DIAGNOSTIC!
1	   66	   6	   1	   1	   1	   HIPOGLICEMIA	   MM	  	  
2	   73	   4	   1	   1	   0	   ANGOR	  INST	   EAM	  
3	   65	   1	   0	   0	   0	   RECTORRAGIA	   HDA	  VARIZES	  ESOF	  
4	   68	   3	   0	   1	   1	   INFEC	  RESP	   FMO	  SEPSIS	  
5	   33	   3	   1	   0	   0	   EAP	  HTA	   CRISE	  HTA	  x	  COCAINA	  -­‐	  GNC	  HVC	  
6	   79	   1	   0	   1	   0	   DIARREIA	   EAM	  
7	   72	   3	   1	   0	   1	   HIPOGLICEMIA	   RABDOMIOLISE	  -­‐	  DM	  DESCOMP	  
Demonstrative ED cases!
	   B_SCr ! B_ eGFR!
SUSCEP
TIBILITY! SCr_S1! CyC_S1! AKI/TAz! DIALYSIS! ICU !
ALL 
SEPSIS! DEAD1! DIAG !
1	   1,5	   49,85	   4	   2,5	   2,65	   1	   0	   0	   0	   0	  	  	  
2	   1,8	   35,53	   4	   2	   1,73	   1	   0	   1	   0	   0	  	  	  
3	   0,7	   120,49	   1	   1,5	   1,28	   1	   0	   0	   0	   0	  	  	  
4	   1	   79,11	   2	   1,6	   1,38	   1	   1	   1	   1	   1	  	  FMO	  
5	   1,8	   46,49	   3	   2,7	   1,89	   1	   0	   0	   0	   0	  	  	  
6	   1	   76,74	   2	   1,1	   0,85	   2	   0	   1	   0	   0	  	  	  
7	   1,8	   39,68	   3	   3,1	   2,46	   1	   1	   0	   1	   1	  SEPSIS	  
Cases: past history and outcome!
Baseline! admission!












GFR ! FU y!
1	   2,7	   25,3	   3,2	   20,79	   12,7	   0	   CKD	  5	   5,50	   11,00	   3,0	  
2	   3,1	   19,0	   5	   10,93	   26,0	   2	   CKD5	  HD	   	   	   2,5	  
3	   1,6	   46,4	   6	   10,10	   2,4	   1	   CKD+AKI	  HD	   	   	   	  
4	   7,4	   7,9	   	   	   0,3	   	   AKI	   	   	   	  
5	   2,1	   38,9	   7,9	   8,44	   10,3	   0	   CKD5	  HD	   	   	   3,0	  
6	   1	   76,7	   10,3	   5,20	   1,0	   1	   CKD+AKI	  HD	   	   	   	  
7	   2,9	   22,9	   5,6	   10,71	   1,0	   	   CKD+AKI	  HD	   	   	   	  
Cases: long term outcome!
Grades of susceptibility 
1 0  eGFR > 90ml/ min/ 1.73 m2 
2 Previous CKD 2 
3 Previous CKD 3 
4 Previous CKD 2/3 + 
 





Adaptado de Mehta R et al; Acute Renal Failure Definitions and Classification: Time for Change? JASN 14: 2003!
Changing concepts!
Biomarkers for AKI 
diagnosis!
Dennen P, Douglas I, Anderson R,: Acute Kidney Injury in the Intensive Care Unit: An update and primer for the 












Clin Sci (Lond) 58:1980!
extensive loss of hepatocyte 
glycogen stores !
Kidney Int 69: 2006!
loss of muscle mass + reduce muscle production !
(hormonal and inflammatory mediators) !
Lancet  2004!
Sepsis-induced hypothermia decrease nonenzymatic conversion of creatine to creatinine!
Infect Immun 67: 6603–6610, 1999!
Serum creatinine fall!
RIFLE criteria for diagnosing AKI!





Serum	  CreaLnine	  Criteria	   Urinary	  Output	  
Criteria	  
Time	  
1	   é	  Cr	  ≥	  0.3	  mg/dL	  or	  é	  	  ≥	  
150-­‐200%	  from	  baseline	  
<	  0.5	  mL/kg/hr	   >	  6	  hrs	  
2	   é	  Cr	  to	  >	  200-­‐300%	  from	  
baseline	  	  
<	  0.5	  mL/kg/hr	   >	  12	  hrs	  
3	   é 	  Cr	  to	  >	  300%	  from	  
baseline	  or	  Cr	  ≥	  4mg/dL	  
with	  an	  acute	  rise	  of	  at	  least	  
0.5	  mg/dL	  
<	  0.5	  mL/kg/hr	  
or	  anuria	  
	  
X	  24	  hrs	  
X	  12	  hrs	  
AKIN staging system for AKI!
Mehta, R. L. et al. Crit. Care. 11, R31 (2007) !




S! 0	  H	   6H	   12H	   24H	   48H	   1W	   DISCH	   AKIN	   death FU! CKD + AKI!
4	   R	   R	   R	   R	   R	   R	   R	   1	   0	   CKD	  5	  
4	   0	   R	   R	   R	   R	   R	   R	   1	   2Y	   CKD5	  HD	  
1	   I	   I	   I	   R	   I	   0	   I	   2	   1Y	   CKD+AKI	  HD	  
2	   R	   0	   R	   R	   R	   F	   F	   3	   	  INT	   AKI	  
3	   R	   R	   R	   R	   R	   0	   R	   1	   0	   CKD5	  HD	  
2	   0	   0	   R	   R	   0	   0	   0	   0	   1Y	   CKD+AKI	  HD	  
3	   R	   R	   R	   R	   R	   0	   0	   1	   	  INT	   CKD+AKI	  HD	  
Cases: AKI diagnosis!
Conceptual model of AKI!
Murugan, R. & Kellum, J. A. (2011) Acute kidney injury: what’s the prognosis?!
Nat. Rev. Nephrol. doi:10.1038/nrneph.2011.13!
About Biomarkers!
Ø  Early prediction and diagnosis of AKI (before SCr)!
Ø  Identify the primary location of injury!
Ø  Discriminate PreRenal, CKD and AKI!
Ø  Predicttion of severity !
Ø  Identify the etiology: ischemic, toxic, septic, combination!
Devarajan	  P,	  Sem	  Nephrol	  2007	  –	  Contrib	  Nephrol	  2008	  
Koyney	  and	  Murray,	  Argutus	  Medical	  
Mehta RL et al. (2007) Crit Care 11: R31"
About Biomarkers!
About Biomarkers for AKI diagnosis!
Sources: Coca et al,2 Parikh et al,3 Bagshaw et al.4. Belcher et al, AJKD 2011 !
Biomarker! Origin in AKI cases ! Significance of rise ! Studied clinical settings !
NGAL	  
serum	  and	  	  
urinary	  
Urine:	  synthesis	  in	  distal	  nephron	  
and	  secreted	  into	  urine	  
Circula?ng:	  synthesized	  
systemically,	  ﬁltered,	  and	  uptaken	  
by	  proximal	  tubular	  cells	  with	  a	  
li^le	  amount	  secreted	  in	  the	  urine	  
Tubular	  injury	  (ischemia	  
and	  nephrotoxins)	  	  
i)	  Early	  detec?on	  of	  AKI	  aber	  cardiac	  surgery,	  
ICU,	  ED,	  and	  aber	  nephrotoxins	  
(ii)	  Risk	  stra?ﬁca?on	  	  
(iii)	  Prognos?c	  marker	  aber	  kidney	  
transplanta?on	  
(iv)	  Monitoring	  interven?onal	  trials	  in	  AKI	  
(v)	  Prognosis	  of	  RRT	  and	  mortality	  
CysC	  
serum	  and	  	  
urinary	  
Produced	  at	  a	  constant	  rate	  by	  
nucleated	  cells,	  ﬁltered,	  and	  
almost	  completely	  reabsorbed	  in	  
the	  proximal	  tubules	  	  
Change	  in	  GFR	  (proximal	  
tubule	  injury)	  	  
(i)  Early	  detec?on	  of	  AKI	  aber	  cardiac	  surgery,	  
ICU	  ,	  ED	  and	  aber	  nephrotoxins	  




Type	  1	  transmembrane	  protein,	  
highly	  expressed	  in	  
dediﬀeren?ated	  proximal	  tubule	  
epithelial	  cells	  aber	  ischemic	  or	  
toxic	  injury	  and	  is	  not	  detectable	  
in	  normal	  ?ssue	  
Tubular	  injury	  (ischemia	  
and	  nephrotoxins)	  	  
	  
(i)	  Early	  detec?on	  of	  AKI	  aber	  cardiac	  surgery	  
and	  aber	  nephrotoxins	  





originates	  from	  tubular	  epithelial	  
cells	  	  
Tubular	  injury	  (ischemia	  
and	  nephrotoxins)	  	  
	  
(i)	  Early	  detec?on	  of	  AKI	  aber	  cardiac	  surgery,	  
in	  ICU	  
(ii)	  Prognos?c	  marker	  aber	  kidney	  
transplanta?on	  
(iii)	  Prognosis	  of	  mortality	  	  
CYSTATIN C!
htttp: structbio.nature.com!
Ø  Cystatin C production is independent from muscle  
mass, constitution of the body, or nutrition!
!
Ø  It is independent or from gender and age!
!
Ø  Probably it is influenced by inflammation and 
malignancy!
!
Ø  It is influenced by very large doses of 
glucocorticoids and thyroid dysfunction!
!
ü free renal filtration !
ü no tubular secretion !
ü no re-entry into circulation !
ü tubular reabsorption followed by 
degradation !
1 2 3 4
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Soto K et al. CJASN 2010 









Cystatin C for differential diagnosis!
RIFLE and GFR based on SCysC ! AKIN and levels of  SCysC !
Cystatin C as marker of severity !
Soto K et al. CJASN 2010 
NGAL !
•  First identified as a !
"neutrophil granule protein!
•  Expressed at very low levels on several tissues!
•  Normally very small amounts in kidney tubules!
•  Induced in injured epithelial cells!
•  The most upregulated gene in the kidney, very early after ischemic or 
nephrotoxic AKI in animals!
Reviewed by P Devarajan . Nephrology 15 (2010) 419–428 and  Biomark Med. 2010 April; 4(2): 265–280.  "
Neutrophil gelatinase-
associated lipocalin!





































 AKI        Pre-R        CKD        NF 
p <0,001 
Soto K et al. 2009 
p <0,001 
NGAL for AKI diagnosis!
NGAL and accurance!
Comparison with Scr! Marker of AKI on CKD !
Urine sediment score to quantitatively evaluate AKI!
Score  Description 
1 RTE cells 0 and granular casts 0 
2 RTE cells 0 and granular casts 1 to 5 or RTE cells 1 to 5 and granular 
casts 0 
3 RTE cells 1 to 5 and granular casts 1 to 5 or RTE cells 0 and granular 
casts 6 to 10 or RTE cells 6 to 20 and granular casts 0 
• Urine profile in ATN: #* renal tubular epithelial cells # #
# # #* coarse granular, muddy brown #
# #   #or mixed cellular casts!
Changing concepts !
Biomarkers not only for accurate diagnosis!
Urine	  biomarker	  groups	  (NGAL,	  IL-­‐18,	  KIM-­‐1	  in	  quar?les	  and	  
urine	  microscopy	  score	  of	  0,	  1,	  2,	  ≥3	  
Primary	  outcome	  occurrence:	  worsened	  AKI	  or	  
in-­‐hospital	  death	  
Ana Luisa Papoila, Faculdade de Ciências Médicas da UNL, CEAUL, Portugal!
BIOMARKERS 
EVALUATION!
“biological characteristics that are objectively measured 
and evaluated as indicators of normal biological processes, 





Classification and prediction !
q   Diagnostic markers!
Used in people with signs or symptoms, to aid in assessing whether  they 
have the condition under study!
!
q   Screening markers!
Used in asymptomatic people, to detect a disease or condition "at an early 
stage !
q   Prognostic markers!
Used in subjects diagnosed with a condition, to predict "subsequent 
outcomes, such as disease relapse or progression!
Understanding!
Ø  Model ‘the risk of disease” (disease outcome) with, for instance, logistic  (or 
Cox) regression. A marker is considered useful if it has a strong effect on risk.!
Ø   Evaluate classification performance – Receiver Operating Characteristic Curve 
(ROC) !
Discretization procedure!
Sensitivity, specificity, predictive values and likelihood ratios!
Understanding!
Results from these two evaluations may be apparently  contradictory:  A 









95% CI: 0.85-0.92 !
S Cystatin C!
AUC=0.87 !
95% CI: 0.83-0.90 !
U CysC !
AUC=0.61 !








LR (+): 3.49 !























Application to risk prediction for AKI markers  !
Understanding!
Changing concepts!
➡  Natural History of AKI leading to chronic disease!
Su^on	  TA	  	  et	  al.	  Kidney	  Int	  62,	  2002;	  modiﬁed	  by	  Okusa	  et	  al.	  CAJSN	  4,	  2009	  
Changing concepts!
Soto	  et.	  al	  2012	  
➡  Partial recovery and No-recovery is more frequent than we 
thought! AKI	  	  
TAz	  	  
Discharge	   2Y	  follow-­‐up	  
➡  Renal survival decrease after an AKI episode!
Changing concepts!
Survival	  to	  CKD4	  	  Survival	  to	  CKD3	  	  
Soto	  et.	  al	  2012	  
55%	  <60ml/min	  
33%	  <30ml/min	  
Searching for predictors of renal outcome !
pNGAL	  and	  CysC	  as	  a	  biomarkeres	  of	  kidney	  evolu?on	  




➡  change our point of view about AKI, as a continuous 
disease that leads to renal imprint !
thanks for sharing our concerns!
➡  we have a lot to do, let’s start using clinical markers !
➡  Applying concepts to clinical practice!
➡  following those patients emphasizing nephroprotection!
➡  let’s work together searching for solutions!
